Sybella Stanley Purchases 3,810 Shares of Smith & Nephew plc (LON:SN) Stock

Smith & Nephew plc (LON:SN) insider Sybella Stanley acquired 3,810 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of GBX 1,101 ($14.25) per share, for a total transaction of £41,948.10 ($54,294.72).

Smith & Nephew Stock Down 1.4 %

Shares of SN opened at GBX 1,067 ($13.81) on Friday. The firm’s 50-day moving average price is GBX 1,070.03 and its two-hundred day moving average price is GBX 1,052.57. The firm has a market capitalization of £11.70 billion, a price-to-earnings ratio of 38.42, a PEG ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22.

Smith & Nephew Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Thursday, March 27th will be given a dividend of $0.23 per share. The ex-dividend date is Thursday, March 27th. This is an increase from Smith & Nephew’s previous dividend of $0.14. This represents a yield of 1.61%. Smith & Nephew’s dividend payout ratio is presently 104.41%.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 1,180 ($15.27) target price on shares of Smith & Nephew in a research report on Tuesday, January 14th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.